DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Proposed Data Collections Available for Public Comment and Recommendations

The Department of Health and Human Services, Office of the Secretary will periodically publish summaries of proposed information collections projects and solicit public comments in compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995. To request more information on the project or to obtain a copy of the information collection plans and instruments, call the OS Reports Clearance Officer on (202) 619–1053.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Project 1. 42 CFR 50 Subpart B: Sterilization of Persons in Federally Assisted Family Planning Projects—0937–0166—Extension no Change—These regulations and informed consent procedures are associated with Federally-funded sterilization services. Selected consent forms are audited during site visits and program reviews to ensure compliance with regulations and the protection of the rights of individuals undergoing sterilization. Burden Estimate for Consent Form—Annual Responses: 40,000; Burden per Response: one hour; Total Burden for Consent Form: 40,000 hours—Burden Estimate for Recordkeeping Requirement—Number of Recordkeepers: 4,000; Average Burden per Recordkeeper: 2.5 hours; Total Burden for Recordkeeping: 10,000 hours. Total Burden: 50,000 hours.

Send comments to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue SW., Washington, DC, 20201. Written comments should be received within 60 days of this notice.

Dated: October 31, 1995.

Dennis P. Williams,

Deputy Assistant Secretary, Budget.

[FR Doc. 95–27614 Filed 11–7–95; 8:45 am]

BILLING CODE 4150–04–M

Food and Drug Administration

Advisory Committee Meetings; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Action.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. The meeting was announced in the Federal Register of October 20, 1995 (60 FR 54233). The amendment is being made to remove probucol, new drug application (NDA) 17–535 (Lorelco®, Hoechst Marion Roussel) for a lipid altering indication from the agenda, and change the time schedule. There are no other changes. This amendment will be announced at the beginning of the open portion of the meeting.

FOR FURTHER INFORMATION CONTACT: Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD–9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Endocrinologic and Metabolic Drugs Advisory Committee, code 12536.

SUPPLEMENTARY INFORMATION: In the Federal Register of October 20, 1995, FDA announced that a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee would be held on November 16 and 17, 1995.

On page 54233, in the first column, the ''*Date, time, and place*'' and the ''*Type of meeting and contact person*'' portions of this meeting are amended, and in the second column, the ''*Open committee discussion*'' portion of the meeting is amended to read as follows:

Date, time, and place. November 16, 1995, 1 p.m., and November 17, 1995, 8 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person. Open public hearing, November 16, 1995, 1 p.m. to 1:30 p.m., unless public participation does not last that long; open committee discussion, 1:30 p.m. and 6 p.m.; open public hearing, November 17, 1995, 8 a.m. to 8:30 a.m., unless public participation does not last that long; open committee discussion, 8:30 a.m. to 2 p.m.; Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD–9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, FAX 301–443–0699, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Endocrinologic and Metabolic Drugs Advisory Committee, code 12536.

Open committee discussion. On November 16, 1995, the committee will hear presentations and discuss data submitted regarding the safety and efficacy of dexfenfluramine hydrochloride, NDA 20–344 (Redux®, Interneuron Pharmaceuticals, Inc.), for an obesity indication, as followup to the meeting of September 28, 1995. On November 17, 1995, the committee will hear presentations and discuss data submitted regarding the safety and efficacy of sodium fluoride USP, NDA 19–975 (Slow Fluoride®, Texas Southwest Medical Center), for an osteoporosis indication.

Dated: November 2, 1995.

David A. Kessler,

Commissioner of Food and Drugs.

[FR Doc. 95–27616 Filed 11–7–95; 8:45 am]

BILLING CODE 4160–01–M

National Institutes of Health

Notice of Meeting; AIDS Research Program Evaluation Working Group

Notice is hereby given of the meeting of the NIH AIDS Research Program Evaluation Working Group Area Review Panel on Drug Discovery on November 29–30, 1995 at the Doubletree Hotel at Lincoln Center, 5410 LBJ Freeway, Dallas, Texas 75240. The meeting will be open to the public from 9:00 am to 12:00 pm on November 29, and the closed portion will be from 1:00 pm to 6:00 pm on November 29, and 7:00 a.m. to 10:30 am on November 30.

The NIH Revitalization Act of 1993 authorizes the Office of AIDS Research (OAR) to evaluate the AIDS research activities of NIH. The NIH AIDS Research Program Evaluation Working Group was established by the OAR to carry out this major evaluation initiative, reviewing and assessing each of the components of the NIH AIDS research endeavor to determine whether those components are appropriately designed and coordinated to answer the critical scientific questions to lead to better treatments, preventions, and a cure for AIDS. Six Area Review Panels were also established to address the following research areas: Natural History and Epidemiology; Etiology and

Pathogenesis; Clinical Trials; Drug Discovery; Vaccines; and Behavioral and Social Sciences Research.

The purpose of the meeting is to seek input from individuals and organizations interested in the evaluation of AIDS research in the areas of therapeutics research as it pertains to drug discovery. Examples of areas under consideration by the panel include basic and applied research in HIV and opportunistic diseases, molecular and structural research, targeted drug discovery programs and animal models. The NIH AIDS Research Program Evaluation Working Group will develop recommendations to be made to the Office of AIDS Research Advisory Council that address the overall NIH AIDS research initiatives, both intramural and extramural, and identify long-range goals in the relevant areas of science. These recommendations will provide the framework for future planning and budget development of the NIH AIDS research program.

There will be a closed session from 1:00 pm to 6:00 pm on November 29, and 7:00 a.m. to 10:30 am on November 30, to update the Panel members on privileged information on institute and center grant and contract portfolios.

The open session from 9:00 am to 12:00 pm will begin with a brief overview of panel activities by members of the panel. The remainder of the meeting will be devoted to presentations from individuals and organizations. The session is open to the public; however, attendance may be limited by seat availability.

Comments should be confined to statements related to the current status NIH AIDS research in the areas of drug discovery for HIV–1 and its associated sequelae and recommendations for consideration by the panel in assessing and reviewing the relevant research in these areas.

Only one representative of an organization may present oral comments. Each speaker will be permitted 5 minutes for their presentation. Interested individuals and representatives of organizations must submit a letter of intent to present comments and three (3) typewritten copies of the presentation, along with a brief description of the organization represented, to the attention of Dr. Judith Feinberg, Office of AIDS Research, NIH, 31 Center Drive, MSC 2340, Building 31, Room 5C08, Bethesda, MD 20892–2340, (301) 496–0358, FAX: (301) 402–8638. Letters of intent and copies of presentations must be received no later than 5:00 pm on Wednesday, November 22.

Any person attending the meeting who does not request an opportunity to speak in advance of the meeting will be allowed to make a brief oral presentation at the conclusion of the meeting, if time permits, and at the discretion of the Chairperson.

Individuals wishing to provide only written statements should send three (3) typewritten copies of their comments, including a brief description of their organization, to the above address no later than 5 pm on November 22. Statements submitted after that date will be accepted. They may not, however, be made available to the Area Review Panel prior to the meeting, though they will be provided subsequently as written testimony.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. Feinberg in advance of the meeting.

Dated: November 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–27636 Filed 11–7–95; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute; Notice of Cancellation of Meeting

Notice is hereby given of the cancellation of the closed meetings of the National Cancer Institute Special Emphasis Panel (SEP) of the National Cancer Institute scheduled for November 13 and 15, 1995, which was published in the Federal Register on October 25 (60 FR 54696).

The meetings were canceled due to administrative complications.

Dated: November 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–27633 Filed 11–7–95; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute; Notice of Meetings of the National Cancer Advisory Board and Its Subcommittees

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the National Cancer Advisory Board, National Cancer Institute, and its Subcommittees on November 27–29, 1995. The meetings of the Board and its Subcommittees will be open to the public to discuss issues relating to committee business as indicated in the notice. Attendance by the public will be limited to space available.

The Committee Management Office, National Cancer Institute, National Institutes of Health, Executive Plaza North, Room 630E, 9000 Rockville Pike, Bethesda, Maryland 20892 (301/496–5708), will provide summaries of the meetings and rosters of the Board members, upon request.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Carole Frank, Committee Management Specialist, at 301/496–5708 in advance of the meeting.

Name of Committee: Subcommittee on Cancer Centers.

Contact Person: Dr. Brian Kimes, Executive Secretary, National Cancer Institute, NIH, Executive Plaza North, room 300, 6130 Executive Blvd., Bethesda, MD 20892–7094; (301) 496–8537.

Date of Meeting: November 27, 1995.

Place of Meeting: Hyatt Regency Bethesda, One Metro Center, Bethesda, MD 20814.

Open: 7 pm to 8 pm.

Agenda: To discuss the cancer centers.

Name of Committee: Subcommittee on Clinical Investigations.

Contact Person: Dr. Robert E. Wittes, Acting Executive Secretary, National Cancer Institute, NIH, Building 31, room 3A52, 9000 Rockville Pike, Bethesda, MD 20892; (301) 496–4291.

Date of Meeting: November 27, 1995.

Place of Meeting: Hyatt Regency Bethesda, One Metro Center, Bethesda, MD 20814.

Open: 8 pm to 9 pm.

Agenda: To discuss cancer clinical investigation issues.

Name of Committee: National Cancer Advisory Board.

Contact Person: Dr. Marvin R. Kalt, Executive Secretary, National Cancer Institute, NIH, Executive Plaza North, room 600A, 6130 Executive Blvd., Bethesda, MD 20892–7045; (301) 496–5147.

Date of Meeting: November 28–29, 1995.

Place of Meeting: Conference Room 10, Building 31C, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

Open: November 28—8 am to approximately 12 noon; November 28—2:30 pm to approximately 5:30 pm; November 29—8 am to approximately 4 pm.

Agenda: Report on activities of the President's Cancer Panel; the Director's Report on the National Cancer Institute; Legislative Update; New Business; Strategic Planning and the Bypass Budget; Division of Basic Sciences Overview; Role of Intramural Board of Scientific Counselors; Division of Clinical Sciences Overview; Division of Cancer Epidemiology and Genetics Overview; Discussion of Intramural Program Integration; Scientific Highlights; Division of Cancer Treatment, Diagnosis and Centers Overview; Division of Cancer Biology Overview; Frederick Cancer Research and Development Center Overview; Grant Application Information and Format of Review Presentations; Subcommittee Reports; Division of Cancer Prevention and Control Overview; and Role of the Extramural Advisory Board.